All In Biotech

Drug Trial Radar · NCT04102371

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 9,041 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,041

Actual

Start

Aug 25, 2020

Primary completion

Dec 1, 2025

Study completion Jan 31, 2026

Sponsor

Lead sponsor
Children's Hospital of PhiladelphiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Children's Hospital; Children's Healthcare of Atlanta; Children's Hospital Colorado; Children's Hospital Los Angeles; University of Pittsburgh; Children's Hospital and Health System Foundation, Wisconsin; Children's Medical Center Dallas; Children's National Research Institute; Children's Hospital Medical Center, Cincinnati; Hasbro Children's Hospital; Ann & Robert H Lurie Children's Hospital of Chicago; Nationwide Children's Hospital; Primary Children's Hospital; Seattle Children's Hospital; St. Louis Children's Hospital; Baylor College of Medicine; University of California, Davis; University of California, San Francisco; University of Michigan; Kidz First Hospital Middlemore; Gold Coast Hospital and Health Service; Queensland Children's Hospital; Westmead Children's Hospital; Sydney Children's Hospitals Network; Perth Children's Hospital; Starship Children's Hospital; Monash Children's Hospital; Women's and Children's Hospital, Australia; Royal Children's Hospital; Royal Darwin Hospital; Virginia Commonwealth University; Alberta Children's Hospital; British Columbia Children's Hospital; Centre Hospitalier Univeritaire Sainte Justine; Centre Hospitalier Universitaire de Quebec; Children's Hospital of Eastern Ontario; The Hospital for Sick Children; IWK Health Centre; Jim Pattison Children's Hospital; Kingston Health Sciences Centre; London Health Sciences Centre; McMaster Children's Hospital; Stollery Children's Hospital; The Children's Hospital of Winnipeg; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Pennsylvania Department of Health; Townsville University Hospital; Hospital nacional de niños Costa Rica; Morgan Stanley Children's Hospital
First posted
Sep 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.

Conditions

  • Shock
  • Septic

Interventions

  • Lactated RingerDrug

    LR is a sterile, nonpyrogenic "balanced" solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5).

  • Normal SalineDrug

    Normal saline solution is an "unbalanced" crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.

  • Plasma-lyteDrug

    PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Major Adverse Kidney Events within 30 days (MAKE30)Time frame: Between randomization and 30 days post enrollment, discharge or death, whichever comes first.

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis: University of California, Davis

    Davis, California

  • CHLA: Children's Hospital Los Angeles

    Los Angeles, California

  • UCSF Benioff Children's Hospital

    San Francisco, California

  • Children's Colorado: University of Colorado

    Denver, Colorado

  • Children's Hospital of Atlanta

    Emory, Georgia

  • Lurie Children's: Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • CS Mott Children's Hospital

    Ann Arbor, Michigan

  • Washington University

    St Louis, Missouri

  • Columbia: New York-Presbyterian Hospital

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Hasbro Children's Hospital

    Providence, Rhode Island

  • Dallas Children's: Children's Medical Center Dallas/UT southwestern

    Dallas, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Primary Children's: University of Utah

    Salt Lake City, Utah

  • Children's Hospital of Richmond at VCU

    Richmond, Virginia

  • Children's National Medical Center

    Columbia, Washington

  • Seattle Children's Hospital

    Seattle, Washington

  • Milwaukee (MCW): Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.